Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET

Current Heart Failure Reports

Volumn 1, Issue 2, 2004, Pages 82-88

  Cleland, John G F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Carvedilol; Chronic Heart Failure; Left Ventricular Systolic Dysfunction; Metoprolol; Nebivolol

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARVEDILOL; METOPROLOL; PROPANOLAMINE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEART LEFT VENTRICLE FUNCTION; HUMAN; MORBIDITY; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TIME;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; HEART FAILURE, CONGESTIVE; HUMANS; METOPROLOL; MORBIDITY; MULTICENTER STUDIES; PROPANOLAMINES; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 12144255450     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-004-0032-5     Document Type: Article

References (32)

1. CIBIS-II Investigators and Committee. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9–13. This is one of the main studies showing that β-blockers reduce mortality compared with placebo. DOI: 10.1016/S0140-6736(98)11181-9
2. Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349–1355. This is one of the main studies showing that β-blockers reduce mortality compared with placebo. DOI: 10.1056/NEJM199605233342101
3. Packer M, Coates AJS, Fowler MD, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651–1658. This is one of the main studies showing that β-blockers reduce mortality compared with placebo. DOI: 10.1056/NEJM200105313442201
4. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 333:2001–2007. This is one of the main studies showing that β-blockers reduce mortality compared with placebo.
5. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001, 344:1659–1667.
6. Nicholas G, Oakley C, Pouleur H, et al.: Xamoterol in severe heart failure. Lancet 1990, 336:1–6. DOI: 10.1016/0140-6736(90)91517-E
7. Poole-Wilson PA, Swedberg K, Cleland JGF, et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7–13. This is a report from the COMET study showing the superiority of carvedilol compared with metoprolol. DOI: 10.1016/S0140-6736(03)13800-7
8. Cleland JGF, Swedberg K, Torp Pedersen C, et al.: Comparison of the effects of metoprolol and carvedilol on symptoms, well-being and quality-adjusted life-years: a description of the ’patient-journey’ in COMET [abstract]. J Am Coll Cardiol 2004, In press. This is a report from the COMET study showing the superiority of carvedilol compared with metoprolol.
9. Bristow MR, Feldman AM, Adams KFJ, Goldstein S: Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? J Card Fail 2003, 9:444–453. DOI: 10.1016/j.cardfail.2003.10.009
10. Poole-Wilson PA, Cleland JGF, Hanrath P, et al.: Rationale and design of the Carvedilol or Metoprolol European Trial in patients with chronic heart failure; the COMET trial. Eur J Heart Fail 2002, 4:321–329. DOI: 10.1016/S1388-9842(02)00025-9
11. Doughty RN, Rodgers A, Sharpe N, MacMahon S: Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomised controlled trials. Eur Heart J 1997, 18:560–565.
12. Freemantle N, Cleland JGF, Young S, et al.: Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999, 318:1730–1737.
13. Dargie HJ: Effects of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385–1390. DOI: 10.1016/S0140-6736(00)04560-8
14. Herlitz J, Dellborg M, Karlson BW, et al.: Similar risk reduction of death of extended-release metoprolol once daily and immediate-release metoprolol twice daily during 5 years after myocardial infarction. Cardiovasc Drugs Ther 1999, 13:127–135. DOI: 10.1023/A:1007736226093
15. Kukin ML, Mannino MM, Freudenberger RS, et al.: Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol 2000, 1:45–50. DOI: 10.1016/S0735-1097(99)00504-5
16. Sandberg A, Blomqvist I, Jonsson UE, Lundborg P: Pharmacokinetic and pharmacodynamic properties of a new controlledrelease formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol 1988, 33:S9-S14. DOI: 10.1007/BF00578406
17. Packer M, Coats AJS, Fowler MB, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651–1658. DOI: 10.1056/NEJM200105313442201
18. Currie PJ, Kelly MJ, McKenzie A, et al.: Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol 1984, 3:203–209. DOI: 10.1016/S0735-1097(84)80449-0
19. Waagstein F, Bristow MR, Swedberg K, et al.: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993, 342:1441–1446. DOI: 10.1016/0140-6736(93)92930-R
20. Packer M, Califf RM, Konstam MA, et al.: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002, 106:920–926. DOI: 10.1161/01.CIR.0000029801.86489.50
21. Bristow MR, Gilbert EM, Abraham WT, et al.: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996, 94:2807–2816. This is the only substantial dose-ranging study of a β-blocker in heart failure. The main thrust of the author’s conclusions was that larger doses were better. However, this is far from clear when the evidence is examined in detail. The lowest dose of β-blocker was associated with the fewest hospitalizations and was just as effective at improving ventricular function as higher doses were in patients with ischemic heart disease.
22. Bristow MR, O’Connell JB, Gilbert EM, et al.: Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994, 89:1632–1642.
23. Uhlir O, Dvorak I, Gregor F, et al.: Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. J Card Fail 1997, 3:271–275. DOI: 10.1016/S1071-9164(97)90026-9
24. Wikstrand J, Hjalmarson A, Waagstein F, et al.: Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomised intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002, 40:491–498. DOI: 10.1016/S0735-1097(02)01970-8
25. Brown JE, McLeod AA, Shand DG: Evidence for cardiac beta 2-adrenoceptors in man. Clin Pharmacol Ther 1983, 33:424–428. DOI: 10.1038/clpt.1983.57
26. Gullestad L, Birkeland K, Nordby G, et al.: Effects of selective beta 2-adrenoceptor blockade on serum potassium and exercise performance in normal men. Br J Clin Pharmacol 1991, 32:201–207.
27. Hryniewicz K, Androne AS, Hudaihed A, Katz SD: Comparative effects of carvedilol and metoprolol on regional vascular response to adrenergic stimuli in normal subjects and patients with chronic heart failure. Circulation 2003, 108:971–976. DOI: 10.1161/01.CIR.0000085070.39873.B1
28. Morgan T: Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994, 26:346.
29. Cohn JN, Archibald DG, Ziesche S, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986, 314:1547–1552. DOI: 10.1056/NEJM198606123142404
30. Cohn JN, Pfeffer MA, Rouleau J, et al.: Adverse mortality effect of central sympathetic inhibition with sustainedrelease moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003, 5:659–667. DOI: 10.1016/S1388-9842(03)00163-6
31. Packer M, Antonopoulos GV, Berlin JA, et al.: Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001, 141:899–907. DOI: 10.1067/mhj.2001.115584
32. Hjalmarson A, Goldstein S, Fagerberg B, et al.: Effects of controlled-release metoprolol on total mortality, hospitalization, and well-being in patients with heart failure: the metoprolol CR-XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2000, 283:1295–1302. This is one of the main studies showing that β-blockers reduce mortality compared with placebo. DOI: 10.1001/jama.283.10.1295